• Je něco špatně v tomto záznamu ?

Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models

Terry A. Gray, Nicola J. MacLaine, Caroline O. Michie, Pavla Bouchalova, Euan Murray, Jacqueline Howie, Roman Hrstka, Magdalena M. Maslon, Rudolf Nenutil, Borek Vojtesek, Simon Langdon, Larry Hayward, Charlie Gourley, Ted R. Hupp

. 2012 ; 378 (1-2) : 20-32.

Jazyk angličtina Země Nizozemsko

Perzistentní odkaz   https://www.medvik.cz/link/bmc15000016

Grantová podpora
NS9812 MZ0 CEP - Centrální evidence projektů

The Anterior Gradient (AGR) genes AGR2 and AGR3 are part of the Protein Disulfide Isomerase (PDI) family and harbour core thioredoxin folds (CxxS motifs) that have the potential to regulate protein folding and maturation. A number of proteomics and transcriptomics screens in the fields of limb regeneration, cancer cell metastasis, pro-oncogenic oestrogen-signalling, and p53 regulation have identified AGR2 as a novel component of these signalling pathways. Curiously, despite the fact that the AGR2 and AGR3 genes are contiguous on chromosome 7p21.1-3, the AGR3 protein has rarely been identified in such OMICs screens along with AGR2 protein. Therefore there is little information on how AGR3 protein is expressed in normal and diseased states. A panel of three monoclonal antibodies was generated towards AGR3 protein for identifying novel clinical models that can be used to define whether AGR3 protein could play a positive or negative role in human cancer development. One monoclonal antibody was AGR3-specific and bound a linear epitope that could be defined using both pep-scan and phage-peptide library screening. Using this monoclonal antibody, endogenous AGR3 protein expression was shown to be cytosolic in four human ovarian cancer subtypes; serous, endometrioid, clear cell, and mucinous. Mucinous ovarian cancers produced the highest number of AGR3 positive cells. AGR3 expression is coupled to AGR2 expression only in mucinous ovarian cancers, whereas AGR3 and AGR2 expressions are uncoupled in the other three types of ovarian cancer. AGR3 expression in ovarian cancer is independent of oestrogen-receptor expression, which is distinct from the oestrogen-receptor dependent expression of AGR3 in breast cancers. Isogenic cancer cell models were created that over-express AGR3 and these demonstrated that AGR3 mediates cisplatin-resistance in mouse xenografts. These data indicate that AGR3 is over-expressed by a hormone (oestrogen-receptor alpha)-independent mechanism and identify a novel protein-folding associated pathway that could mediate resistance to DNA-damaging agents in human cancers. Copyright 2012 Elsevier B.V. All rights reserved.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15000016
003      
CZ-PrNML
005      
20170411104817.0
007      
ta
008      
150106s2012 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jim.2012.01.013 $2 doi
035    __
$a (PubMed)22361111
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a ne
100    1_
$a Gray, Terry $u p53 Signal Transduction Group, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
245    10
$a Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models / $c Terry A. Gray, Nicola J. MacLaine, Caroline O. Michie, Pavla Bouchalova, Euan Murray, Jacqueline Howie, Roman Hrstka, Magdalena M. Maslon, Rudolf Nenutil, Borek Vojtesek, Simon Langdon, Larry Hayward, Charlie Gourley, Ted R. Hupp
520    9_
$a The Anterior Gradient (AGR) genes AGR2 and AGR3 are part of the Protein Disulfide Isomerase (PDI) family and harbour core thioredoxin folds (CxxS motifs) that have the potential to regulate protein folding and maturation. A number of proteomics and transcriptomics screens in the fields of limb regeneration, cancer cell metastasis, pro-oncogenic oestrogen-signalling, and p53 regulation have identified AGR2 as a novel component of these signalling pathways. Curiously, despite the fact that the AGR2 and AGR3 genes are contiguous on chromosome 7p21.1-3, the AGR3 protein has rarely been identified in such OMICs screens along with AGR2 protein. Therefore there is little information on how AGR3 protein is expressed in normal and diseased states. A panel of three monoclonal antibodies was generated towards AGR3 protein for identifying novel clinical models that can be used to define whether AGR3 protein could play a positive or negative role in human cancer development. One monoclonal antibody was AGR3-specific and bound a linear epitope that could be defined using both pep-scan and phage-peptide library screening. Using this monoclonal antibody, endogenous AGR3 protein expression was shown to be cytosolic in four human ovarian cancer subtypes; serous, endometrioid, clear cell, and mucinous. Mucinous ovarian cancers produced the highest number of AGR3 positive cells. AGR3 expression is coupled to AGR2 expression only in mucinous ovarian cancers, whereas AGR3 and AGR2 expressions are uncoupled in the other three types of ovarian cancer. AGR3 expression in ovarian cancer is independent of oestrogen-receptor expression, which is distinct from the oestrogen-receptor dependent expression of AGR3 in breast cancers. Isogenic cancer cell models were created that over-express AGR3 and these demonstrated that AGR3 mediates cisplatin-resistance in mouse xenografts. These data indicate that AGR3 is over-expressed by a hormone (oestrogen-receptor alpha)-independent mechanism and identify a novel protein-folding associated pathway that could mediate resistance to DNA-damaging agents in human cancers. Copyright 2012 Elsevier B.V. All rights reserved.
536    __
$c Grant Number: C483/A10706 (United Kingdom Cancer Research UK)
536    __
$c Grant Number: C483/A6354 (United Kingdom Cancer Research UK)
536    __
$c Grant Number: C483/A8033 (United Kingdom Cancer Research UK)
536    __
$c Grant Number: (United Kingdom Biotechnology and Biological Sciences Research Council)
590    __
$a bohemika - dle Pubmed
650    02
$a sekvence aminokyselin $7 D000595
650    02
$a zvířata $7 D000818
650    02
$a Antineoplastic Agents $x pd [Pharmacology]
650    12
$a Carrier Proteins $x ge [Genetics]
650    12
$a Carrier Proteins $x me [Metabolism]
650    02
$a Cell Line, Tumor
650    12
$a Cisplatin $x pd [Pharmacology]
650    02
$a Drug Resistance, Neoplasm
650    02
$a Epitope Mapping $x mt [Methods]
650    02
$a Female
650    _2
$a lidé $7 D006801
650    02
$a Mice
650    02
$a Mice, Nude
650    02
$a Molecular Sequence Data
650    12
$a Neoplasm Proteins $x ge [Genetics]
650    12
$a Neoplasm Proteins $x me [Metabolism]
650    12
$a Ovarian Neoplasms $x dt [Drug Therapy]
650    02
$a Ovarian Neoplasms $x ge [Genetics]
650    12
$a Ovarian Neoplasms $x me [Metabolism]
650    02
$a Proteins $x ge [Genetics]
650    02
$a Proteins $x me [Metabolism]
650    02
$a Receptors, Estrogen $x ge [Genetics]
650    02
$a Receptors, Estrogen $x me [Metabolism]
650    02
$a Transfection $x mt [Methods]
650    12
$a Tumor Markers, Biological $x ge [Genetics]
650    12
$a Tumor Markers, Biological $x me [Metabolism]
650    02
$a Xenograft Model Antitumor Assays
700    1_
$a MacLaine, Nicola J. $u p53 Signal Transduction Group, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
700    1_
$a Michie, Caroline $u Ovarian Cancer Genetics and Translational Research, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, Scotland, UK
700    1_
$a Bouchalová, Pavla $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Murray, Euan $u p53 Signal Transduction Group, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
700    1_
$a Howie, Jacqueline $u p53 Signal Transduction Group, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
700    1_
$a Hrstka, Roman $7 xx0077297 $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Maslon, Magda M. $u p53 Signal Transduction Group, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
700    1_
$a Nenutil, Rudolf $7 xx0057842 $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Vojtesek, Borek $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Langdon, Simon $u Edinburgh Breakthrough Research Unit and Division of Pathology, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, Scotland, UK
700    1_
$a Hayward, Larry $u Edinburgh Breakthrough Research Unit and Division of Pathology, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, Scotland, UK
700    1_
$a Gourley, Charlie $u Ovarian Cancer Genetics and Translational Research, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, Scotland, UK
700    1_
$a Hupp, Ted R. $u p53 Signal Transduction Group, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
773    0_
$t Journal of immunological methods $x 0022-1759 $g Roč. 378, č. 1-2 (2012), s. 20-32 $w MED00010028
910    __
$a ABA008 $b B 1400 $c 513 a $y 4 $z 0
990    __
$a 20150106104304 $b ABA008
991    __
$a 20170411105116 $b ABA008
999    __
$a ok $b bmc $g 1057041 $s 882734
BAS    __
$a 3
BMC    __
$a 2012 $b 378 $c 1-2 $d 20-32 $i 0022-1759 $m Journal of immunological methods $x MED00010028
GRA    __
$a NS9812 $p MZ0
LZP    __
$a 2015-01/ab

Najít záznam

Citační ukazatele

    Možnosti archivace